Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
69.8M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
45.3M
-
Shares change
-
+2.19M
-
Total reported value, excl. options
-
$1.92B
-
Value change
-
+$61.7M
-
Put/Call ratio
-
0.11
-
Number of buys
-
74
-
Number of sells
-
-47
-
Price
-
$42.32
Significant Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q1 2022
148 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock as of Q1 2022.
Kymera Therapeutics, Inc. - Common Stock (KYMR) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.3M shares
of 69.8M outstanding shares and own 64.87% of the company stock.
Largest 10 shareholders include Atlas Venture Life Science Advisors, LLC (6.88M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.9M shares), BVF INC/IL (3.59M shares), BlackRock Inc. (3.42M shares), WELLINGTON MANAGEMENT GROUP LLP (3.23M shares), VANGUARD GROUP INC (2.84M shares), Redmile Group, LLC (2.62M shares), BAKER BROS. ADVISORS LP (2.38M shares), STATE STREET CORP (2.09M shares), and FMR LLC (1.92M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.